ABSTRACT
OBJECTIVE: To investigate the frequency of leukotriene C(4) synthase gene A (LTC(4)S A) -444 C polymorphism in asthmatics of Chinese Han nationality in Southwest China and to evaluate its relevance to clinical responsiveness to leukotriene receptor antagonist. METHODS: A hundred and fifty asthmatics and 146 healthy blood donors were recruited. The genotype distribution of A/C polymorphism of LTC(4)S A(-444)C gene was analyzed by RELP (restriction fragment length polymorphism). Eighty asthmatics were randomly recruited for a 4 week prospective trial of montelukast and their clinical response to montelukast was evaluated by ACQ and pulmonary function. Urine LTE(4) was detected by ELISA (enzyme linked immunosorbent assay) in asthma patients before and after treatment. RESULTS: In the 150 asthma patients, the frequencies of A and C alleles at -444 locus of LTC(4)S gene were 83.7% and 16.3%, respectively, and the genotype frequencies of AA and AC/CC were 70.7% and 29.3%, respectively. In the 146 healthy blood donors, the frequencies of A and C alleles at -444 locus of LTC(4)S gene were 87.0% and 13.0%, respectively, and the genotype frequencies of AA and AC/CC were 76.7% and 23.3%, respectively. There was no significant difference in LTC(4)S A(-444)C polymorphism between the asthmatics and the healthy controls (chi(2) = 1.393, 1.301, P = 0.238, 0.25 4, P > 0.05). The asthmatics with the C(-444) allele were younger than the asthmatics with AA with earlier onset age and longer duration of disease compared to those with AA (both P < 0.05). However, there were no significant differences between the two groups in clinical and lung function parameters. Four-week montelukast therapeutic trial demonstrated that asthmatic patients with AC/CC genotype had better response than those with AA genotype and this difference was related to urine LTE(4) level (F = 12.01, P = 0.011). CONCLUSION: In a Southwest Chinese Han population LTC(4)S A(-444)C polymorphism might be a determinant factor in the clinical response of asthma to leukotriene receptor antagonists.
